title: [Malignant paranasal sinus tumors. Diagnosis, therapy and results].
abstract: BACKGROUND
  Malignant neoplasmas of the paranasal sinuses are rare and present usually in advanced tumor stage due to the lack of early clinical symptoms.
  
  
  METHODS
  In the last 10 years, 63 patients with paranasal malignancies were treated at the Department of Otolaryngology, Head and Neck Surgery of the University of Würzburg. 33% of the patients showed an occupational exposition (wood-processing or metal industry). At the time of the first visit to our institution 95% of the patients presented with an extensive disease, staged T3 and T4. Adenocarcinoma (24%), squamous cell carcinoma (22%) and malignant melanoma (19%) were the most common histologies. Surgery combined with radiotherapy was the treatment strategy in 55 patients (87%).
  
  
  RESULTS
  Patients with a complete surgical resection showed a higher 5-year-survival rate (77%) than patients with an incomplete resection (56%). In 38% (n=21) of the patients treated with surgery and radiotherapy, a local recurrence of the tumor was observed. This recurrence localised in the skull base and/or the orbita/periorbita occurred most frequently in the first (46%) or the second year (31%).
  
  
  CONCLUSIONS
  The prognosis of malignant paranasal tumors depends mainly on the control of the local tumor growth. Modern strategies of surgical treatment in combination with radiotherapy need to be implemented in an effort to achieve a continuous remission.
authors.affiliation: Klinik und Poliklinik für Hals-, Nasen- und Ohrenkranke, Kopf- und Halschirurgie, Bayerische Julius-Maximilians-Universität Würzburg. baier_g@klinik.uni-wuerzburg.de
authors.forename: G
authors.initials: G
authors.lastname: Baier
authors.forename: C
authors.initials: C
authors.lastname: Völter
authors.forename: I
authors.initials: I
authors.lastname: Steigerwald
authors.forename: J
authors.initials: J
authors.lastname: Müller
authors.forename: K
authors.initials: K
authors.lastname: Schwager
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002648:Child; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D009784:Occupational Diseases / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D010255:Paranasal Sinus Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate